Illustration: Aïda Amer/Axios
Ligand Pharmaceuticals has agreed to buy Xoma Royalty in a deal worth $739 million, the companies announced Monday.
Why it matters: The deal expands Ligand's business, nearly doubling its portfolio of Phase 2 and 3 assets.
